A Discussion of Best Practices and Unique Models

Wednesday | January 31, 2018
at The NYSCF Research Institute
KEYNOTE

THE ROBERTSON THERAPEUTIC DEVELOPMENT FUND: A Novel Funding Mechanism to Advance Academic Assets

Bruce R. Conway, PhD
Program Director
Robertson Therapeutic Development Fund
The Rockefeller University

REGISTRATION AND BREAKFAST

WELCOME

Susan L. Solomon, JD
Chief Executive Officer
The New York Stem Cell Foundation Research Institute

Betsy Myers, PhD
Program Director for Medical Research
Doris Duke Charitable Foundation

TOURS OF NYSCF AND BREAK
TRANSLATIONAL SCIENCE:
A Discussion of Best Practices and Unique Models

MODERATOR
Caren A. Heller, MD, MBA
Chief Scientific Officer
Crohn’s & Colitis Foundation

PANELISTS
Michael L. Batten, MD, MBA
Director
JDRF T1D Fund

Bruce R. Conway, PhD
Program Director
Robertson Therapeutic Development Fund
The Rockefeller University

Andres Hurtado-Lorenzo, PhD
Director of Translational Research
Crohn’s & Colitis Foundation

Elizabeth Schwarzbach, PhD
Vice President, Business Development
The New York Stem Cell Foundation Research Institute

CONCLUSION
Maryrose Franko, PhD
Executive Director
Health Research Alliance

LUNCH AND NETWORKING
Bruce Conway is the Director of the Robertson Therapeutic Development Fund, a novel funding mechanism to advance the groundbreaking discoveries at The Rockefeller University. Bruce earned his PhD in Pharmacology at the Medical College of Virginia and completed his postdoctoral fellowship at the University of Massachusetts Medical Center. He then joined Johnson & Johnson Pharmaceutical Research and Development where he championed the progression of three compounds into the clinic, one of which resulted in the FDA approval of a novel, first-in-class treatment for type 2 diabetes Invokana®. In 2006, he moved to the Institutes for Pharmaceutical Discovery as the Senior Director of Biology where he oversaw the day-to-day operations of the Biology, Pharmacology and DMPK teams. In 2013, Dr. Conway transitioned to academia and served as the “Executive-in-Residence” at Columbia University. In 2014, Dr. Conway joined The Rockefeller University where he serves in his current position. He serves on the Faculty within the Clinical Center for Translational Science and as an advisor to the Tri-Institutional Therapeutic Discovery Institute, Pfizer’s Center for Therapeutic Innovation, Columbia Technology Ventures, and 1st Pitch Life Sciences NYC.

Dr. Caren Heller is the Chief Scientific Officer at the Crohn’s & Colitis Foundation where she is responsible for all mission-related activities, including a diverse research portfolio, education, support and advocacy programs.

Working with leading scientists and clinicians, Dr. Heller is responsible for investing more than $30 million in IBD research and infrastructure, including IBD Plexus, an innovative disease-specific big data platform, IBD Qorus, a quality of healthcare improvement network, entrepreneurial investing, industry-academic drug discovery initiatives, and investigator-initiated research projects. She has also been instrumental in focusing the Foundation on clinical trials activities including establishing a new clinical trials initiative for patients and expanding the activities of the Foundation's clinical research networks to include an adult, pediatric, and surgery research network.
Prior to joining the Foundation as its first chief scientific officer in 2014, Dr. Heller was Associate Dean for Intercampus and Industry Initiatives at Weill Cornell Medical College. Dr. Heller has prior work experience as a consultant or an employee at large biopharmaceutical companies and in start-up companies related to pharmaceutical drug development, medical/commercial evaluation of new therapies and technologies, and strategic planning for new program and product opportunities.

Dr. Heller received her BA from Harvard University, her MD from Columbia University’s College of Physicians & Surgeons, and an MBA from The University of Chicago Booth Graduate School of Business. She is board certified in internal medicine and trained in rheumatology and clinical pharmacology. She currently serves on the National Diabetes, Digestive and Kidney Diseases Advisory Council of the NIH.

---

**Panelist**  

**Michael L. Batten, MD, MBA**  
Director  
JDRF T1D Fund

Michael L. Batten, MD, MBA, is a director in the JDRF T1D Fund. In this role, he focuses on advancing scientifically and commercially promising Type 1 Diabetes research by facilitating venture creation of and syndicated venture investments in companies pursuing the best opportunities to prevent, treat and ultimately cure T1D. By leveraging his experience and relationships with key stakeholders in academia, industry and venture capital, he brings a unique skill set to JDRF that compliments the organization’s efforts to translate novel, innovative science into lifesaving therapies for Type 1 Diabetes patients.

Previously, Dr. Batten invested in both private and public healthcare companies as the life science portfolio manager at Merrill Lynch’s Strategic Investment Group and as a founding member of the investment team of the Health Holdings group at Caxton Associates. Prior to his investing roles, Michael was a member of Pfizer’s Business Development group where he led multiple transactions and was instrumental in the creation of Pfizer Venture Investments, the strategic venture capital arm of Pfizer.

Dr. Batten received his BS in Mechanical Engineering from North Carolina State University, his MD from The University of North Carolina – Chapel Hill School of Medicine, trained in Ophthalmology at New York University, and received his MBA at The Wharton School of The University of Pennsylvania with a concentration in healthcare management and finance.
PANELIST

**Andres Hurtado-Lorenzo, PhD**
Director of Translational Research
Crohn’s & Colitis Foundation

Dr. Andres Hurtado-Lorenzo is the Director of Translational Research at the Crohn’s and Colitis Foundation. He is responsible for planning and oversight of the Foundation’s translational research portfolio that funds several research initiatives. These initiatives aim to identify opportunities to translate observations in the laboratory and clinic into interventions that reach and benefit patients; from therapeutics and diagnostics to medical devices and procedures. The Foundation’s translational initiatives include microbiome, genetics, precision medicine, environmental triggers, and a venture philanthropy initiative focused on accelerating product discovery and development through entrepreneurial investing.

He has extensive drug discovery and development experience gained both in pharmaceutical and biotechnology industry. As industry scientist he led research and development programs for neurological and rare diseases at Wyeth, Pfizer and Proteostasis Therapeutics, all the way from discovery to early clinical development.

He obtained his PhD in Molecular Medicine from the University of Manchester in the UK, where he contributed to pioneer the field of viral gene therapy for neurodegenerative diseases. He completed his postdoctoral work at Harvard Medical School, Massachusetts General Hospital and Columbia University, where he conducted groundbreaking research focused on molecular mechanisms of autophagy and other protein degradation pathways and their role in health and disease.

PANELIST

**Elizabeth Schwarzbach, PhD**
Vice President, Business Development
The NYSCF Research Institute

Elizabeth (Liz) Schwarzbach is currently the Vice President, Business Development at The New York Stem Cell Foundation Research Institute (NYSCF) where she works closely with the executive team to foster and grow partnerships, new initiatives, and NYSCF’s role in the global biotech and research community. Liz has an extensive background in both industry and academia in drug discovery and development. She began her career as a biologist in Merck Research Labs, leading numerous engagements with pharma, biotech, diagnostics, and financial services clients as a manager with L.E.K. Consulting, then transitioned to GlaxoSmithKline R&D Strategy, and spent a short time as Head, Business Development for Axovant Sciences. As a non-profit leader, Liz served as Vice President, Chief of Staff of Sanford Burnham Prebys Medical Discovery Institute, a private research institute with 1,100 employees across two campuses in La Jolla, California and Lake Nona, Florida. Liz completed her PhD training in Pharmacology at the University of Pennsylvania School of Medicine.
Translational Science: A Discussion of Best Practices and Unique Models

The New York Stem Cell Foundation Research Institute
The Doris Duke Charitable Foundation and The New York Stem Cell Foundation are pleased to co-host the Inaugural Tri-State Area Regional Members’ Meeting in support of the Health Research Alliance’s mission to maximize the impact of biomedical research to improve human health.

PROGRAM COMMITTEE
Katrina Bandong, MS
Richard Ha
Caren A. Heller, MD, MBA
Gérard Honig, PhD
Maneesh Kumar, MD, PhD
Yung S. Lie, PhD
Kristin Smith

CO-HOSTS